14 episodes

PeerView is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerView Gastroenterology CME/CNE/CPE Audio Podcast PeerView Press

    • Science

PeerView is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Amit Singal, MD, MS - MasterClass & Tumor Board⁠—Joining Forces in Hepatocellular Carcinoma: Enhancing Multidisciplinary Care in an Era of New Therapeutic Solutions

    Amit Singal, MD, MS - MasterClass & Tumor Board⁠—Joining Forces in Hepatocellular Carcinoma: Enhancing Multidisciplinary Care in an Era of New Therapeutic Solutions

    Go online to PeerView.com/GWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView MasterClass and Tumor Board video activity, based on an educational session from The Liver Meeting® (American Association for the Study of Liver Diseases) in Boston, features a panel of hepatology, oncology, surgery, and interventional radiology experts, who provide their clinical perspectives on cutting-edge science that has validated, newly available systemic treatment options in HCC. Coupled with each MasterClass, the Tumor Board segments feature reflective case-centered discussions on the crucial role that hepatology clinicians serve across the HCC continuum of care. Upon completion of this activity, participants should be better able to: Evaluate the safety and efficacy data of multikinase and checkpoint inhibitors and antiangiogenic therapy indicated for advanced HCC, Summarize emerging clinical evidence on the use of novel systemic options in conjunction with or as an alternative to continued LRT for patients with intermediate HCC, Implement multidisciplinary team-based approaches to develop safe, personalized treatment algorithms that utilize novel components for patients with HCC

    • 1 hr 30 min
    Ghassan Abou-Alfa, MD, MBA - Composing Personalized HCC Treatment Strategies: Insights on Harmonizing Patient Care With a Multidisciplinary Ensemble

    Ghassan Abou-Alfa, MD, MBA - Composing Personalized HCC Treatment Strategies: Insights on Harmonizing Patient Care With a Multidisciplinary Ensemble

    Go online to PeerView.com/XKX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hepatocellular carcinoma (HCC) is an aggressive, complex disease and is a leading cause of cancer-related deaths worldwide. Research endeavors to mitigate HCC mortality have led to rapid advances, especially in the past two years. Today, clinicians specializing in HCC have various treatment options to select for their patients across the spectrum of the disease, and the therapeutic landscape continues to evolve with promising results from ongoing clinical trials investigating novel approaches. This PeerView MasterClass and Tumor Board on-demand educational activity, based on a symposium held adjunct to the 13th Annual Conference of the International Liver Cancer Association (ILCA 2019), features a panel of multidisciplinary HCC experts who review pivotal evidence on available TKI, antiangiogenic, and checkpoint inhibitor therapies and their optimal treatment sequencing strategies, as well as emerging data on novel combinations and innovative modalities for early- to advanced-stage disease. The experts weave the science into real-world case scenarios, helping to translate the data into practical experiences in the HCC clinic. Upon completion of this activity, participants should be better able to: Summarize recent safety and efficacy evidence of available targeted therapies, such as multikinase inhibitors and monoclonal antibodies, for HCC, Evaluate the significance of new data and ongoing clinical trials with checkpoint inhibitors as treatment options for HCC, Review the potential use of systemic treatments in novel multimodal strategies for intermediate HCC, Construct safe and effective treatment plans across multiple lines of therapy for patients with HCC based on multidisciplinary team–based strategies

    • 1 hr 15 min
    Matthew T. Ballo, MD, FACR - Readying the Modern Radiation Oncology Practice for Incorporation of a Fourth Modality in Cancer Treatment: Understanding the Science, Evidence & Clinical Application Across a Range of Solid Malignancies

    Matthew T. Ballo, MD, FACR - Readying the Modern Radiation Oncology Practice for Incorporation of a Fourth Modality in Cancer Treatment: Understanding the Science, Evidence & Clinical Application Across a Range of Solid Malignancies

    Go online to PeerView.com/APQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management paradigms of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM) and are set to evolve the standards of care for patients with other solid tumors as well. In this activity, based on a recent live symposium held in Chicago, Illinois, radiation and medical oncology experts review cutting-edge advancements in cancer technology, such as TTFields, and offer insight and case discussions illustrating the appropriate integration of innovative solutions into cancer management. Moreover, the expert panel reviews multimodal strategies in GBM and examines the impact of novel treatment modalities available for MPM, as well as new approaches that are emerging for other tumors, including thoracic, pancreatic, liver, and ovarian cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Assess the latest safety and efficacy evidence on innovative strategies available for the therapeutic management of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Cite the latest evidence and ongoing clinical trials on novel treatments, including combining TTFields or radiotherapy with systemic therapy, in multiple tumor types, such as lung, pancreatic, liver, and ovarian cancers, across different treatment settings, Plan strategies to integrate novel technologies into the therapeutic management of patients with cancer, including through enrollment in clinical trials

    • 1 hr 19 min
    Sorayah Bourenane, MSN, RN, CNL / Marianne Davies, DNP, ACNP, AOCNP - Identification, Triage, and Management of Immune-Related Adverse Effects in Patients With Cancer Presenting to the Emergency Department: Practical Guidance for Emergency Nurses

    Sorayah Bourenane, MSN, RN, CNL / Marianne Davies, DNP, ACNP, AOCNP - Identification, Triage, and Management of Immune-Related Adverse Effects in Patients With Cancer Presenting to the Emergency Department: Practical Guidance for Emergency Nurses

    Go online to PeerView.com/AMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Treatment of cancer has been transformed by the new immune checkpoint inhibitor class of agents that have shown remarkable benefit in many different types of tumors, but they can also cause unusual immune-related adverse effects (irAEs) that can affect any organ system. Expanding use of these immunotherapies in oncology means that emergency medicine professionals can expect to encounter an increasing number of patients experiencing various irAEs in emergency departments. Timely recognition, accurate diagnosis, and effective management of irAEs can ensure that patients derive maximum benefit from these therapies, and emergency nurses have an important role to play in evaluating and triaging these patients. This CNE educational on-demand activity combines lessons on everything emergency nurses need to know about cancer immunotherapies and irAEs with case discussions and practical guidance for keeping patients with cancer safe in the era of immuno-oncology. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-related adverse effects (irAEs), Characterize the presenting symptoms of the spectrum of irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by emergency nurses and other professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for the recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology specialists

    • 45 min
    Ghassan Abou-Alfa, MD, MBA - ‘How I Think, How I Treat’—Embarking on a New Treatment Era in Hepatocellular Carcinoma: A Personal Take on Integrating Recent Evidence Into the Continuum of Care for Patients With HCC

    Ghassan Abou-Alfa, MD, MBA - ‘How I Think, How I Treat’—Embarking on a New Treatment Era in Hepatocellular Carcinoma: A Personal Take on Integrating Recent Evidence Into the Continuum of Care for Patients With HCC

    Go online to PeerView.com/XEJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Multiple new drug approvals and positive clinical trial outcomes have set the stage for the wider integration of novel therapeutics across the treatment spectrum of hepatocellular carcinoma (HCC). These developments have established multiple targeted and immunotherapy agents as options in advanced disease while also mapping potential future applications in intermediate stage HCC and beyond. Future care will depend on the successful integration of newer tyrosine kinase inhibitor (TKI)-based approaches with established and emerging immune checkpoint inhibitors across patient populations and lines of therapy. This PeerView “How I Think, How I Treat” activity, based on a symposium held during the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, offers an inside look at how experts translate important new data and navigate the current HCC landscape in order to provide the most benefit for their patients. This activity also features important insights on how to utilize newly approved TKIs and checkpoint inhibitors across disease and treatment settings, as well as provides expert thoughts on the next wave of emerging solutions that leverage the power of novel therapies across the continuum of HCC. Upon completion of this activity, participants should be better able to: Summarize emerging clinical evidence on the use of novel systemic treatments, including targeted and immunotherapeutic agents, in a range of HCC treatment settings and populations, Apply recent safety and efficacy data on targeted therapies into clinical practice to enhance aspects of HCC care, including treatment sequencing and managing treatment-related adverse events, Integrate immunotherapeutic strategies for the management of patients with advanced HCC, including through optimal treatment selection and via management of immune-related adverse events, Identify innovative treatment strategies currently being assessed in clinical trials across the spectrum of HCC, such as immunotherapy combinations, combinations of novel agents with locoregional therapies, and early transition to systemic treatment, among others.

    • 1 hr 45 min
    Johanna C. Bendell, MD - Stories From the Pancreatic Cancer CaseBook: Taking the Road to Improved Outcomes With Modern Therapeutic Concepts and Innovative Treatments

    Johanna C. Bendell, MD - Stories From the Pancreatic Cancer CaseBook: Taking the Road to Improved Outcomes With Modern Therapeutic Concepts and Innovative Treatments

    Go online to PeerView.com/RRU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Pancreatic cancer has retained its fearsome reputation amidst the clinical advances made in recent years in other solid tumor settings, and it is now the fourth leading cause of cancer death in men and women in the United States. But recently, new science has taken important steps in meeting the challenges posed by this disease. Beginning with the validation of modern chemotherapy platforms, which now can be sequenced to improve clinical benefits, clinicians are increasingly able to select more potent—and soon, more targeted—options for disease management. In the wake of these advances, other innovative therapies are being rapidly developed, from stroma- and BRCA-targeting agents, to immunotherapy and tumor treating fields. In this PeerView CaseBook on-demand activity based on a recent live symposium held at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, our expert panel profiles the modern management of pancreatic cancer, including the evidence for more personalized approaches to treatment decision-making across the disease spectrum. The panelists highlight new directions in therapeutic sequencing, explore the role of clinical trials as a driver for validating innovative strategies, and use real-world cases to crystalize strategies for initial therapy selection and sequencing, the function of biomarker testing, and patient referral to clinical trials. This engaging CaseBook activity also highlights important “patient voice” materials developed in collaboration with Let’s Win, an online community (letswinpc.org) for sharing information about innovative, science-based treatments for Pancreatic Cancer. Let’s Win is an affiliate of the Lustgarten Foundation. Upon completion of this activity, participants will be able to: Summarize recent evidence on the use of modern cytotoxic platforms and chemotherapy sequencing approaches, targeted agents, and tumor treating field therapy, among others, in the setting of advanced pancreatic cancer, Recommend appropriate therapeutic platforms across multiple lines of therapy for patients with advanced pancreatic cancer based on available evidence, guideline recommendations, and disease- and patient-specific characteristics, Identify patients with pancreatic cancer who are candidates for experimental therapy in a clinical trial, Manage adverse events associated with established cytotoxic and emerging therapies for pancreatic cancer.

    • 1 hr 38 min

Top Podcasts In Science

Listeners Also Subscribed To

More by PeerView Press